Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Completed dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed across United States, Europe and South Korea; enrolling standard of care chemotherapy combination expansion cohorts; on track for initial monotherapy data, including antitumor response for first-line non-small cell lung cancer (NSCLC) cohort in Q1 2027
Covered in this story
Call it yourself
No calls on $CBIO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Crescent Biopharma →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.